pegozafermin (BIO89-100) / 89Bio  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pegozafermin (BIO89-100) / 89Bio
NCT06318169: A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Recruiting
3
1050
US
Pegozafermin, BIO89-100, Placebo
89bio, Inc.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
12/26
02/29
NCT06419374: A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Recruiting
3
762
US
Pegozafermin, BIO89-100, Placebo
89bio, Inc.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
06/28
08/31
ENTRUST, NCT05852431: To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

Recruiting
3
360
Europe, Canada, US, RoW
Pegozafermin, Placebo
89bio, Inc.
Severe Hypertriglyceridemia
08/25
09/26

Download Options